Lynn Seely

7.1k total citations · 3 hit papers
15 papers, 5.2k citations indexed

About

Lynn Seely is a scholar working on Pharmacology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lynn Seely has authored 15 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 4 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lynn Seely's work include Cholinesterase and Neurodegenerative Diseases (5 papers), Metabolism, Diabetes, and Cancer (3 papers) and Attention Deficit Hyperactivity Disorder (2 papers). Lynn Seely is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (5 papers), Metabolism, Diabetes, and Cancer (3 papers) and Attention Deficit Hyperactivity Disorder (2 papers). Lynn Seely collaborates with scholars based in United States, Russia and Sweden. Lynn Seely's co-authors include Mary‐Ellen Taplin, Mohammad Hirmand, Howard I. Scher, Paul N. Mainwaring, John D. Hainsworth, Fred Saad, Andrew J. Armstrong, Karim Fizazi, Aude Fléchon and Kurt Miller and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Diabetes.

In The Last Decade

Lynn Seely

14 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

2012 3.3k citations Howard I. Scher, Karim Fizazi et al. New England Journal of Medicine profile →
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

2010 809 citations Howard I. Scher, Tomasz M. Beer et al. The Lancet profile →
Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery

2006 479 citations Michael S. Conte, Dennis F. Bandyk et al. Journal of Vascular Surgery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lynn Seely United States	7	4.0k	1.3k	1.3k	1.2k	1.0k	15	5.2k
Hiroji Uemura Japan	31	2.5k 0.6×	800 0.6×	1.0k 0.8×	809 0.7×	804 0.8×	165	4.1k
B. Yа. Alekseev Russia	32	5.4k 1.4×	1.5k 1.1×	2.2k 1.7×	2.3k 1.9×	2.2k 2.1×	316	7.7k
Joshi J. Alumkal United States	31	2.8k 0.7×	664 0.5×	1.8k 1.4×	1.3k 1.0×	1.7k 1.7×	136	4.7k
David T. Hung United States	17	2.3k 0.6×	616 0.5×	2.2k 1.7×	1.8k 1.5×	759 0.7×	24	7.1k
Lisa G. Horvath Australia	46	2.5k 0.6×	525 0.4×	2.4k 1.9×	1.6k 1.3×	2.2k 2.1×	198	6.0k
Julie N. Graff United States	25	2.3k 0.6×	638 0.5×	664 0.5×	769 0.6×	1.2k 1.1×	104	3.2k
Masaki Shiota Japan	39	2.0k 0.5×	240 0.2×	2.3k 1.8×	1.1k 0.9×	945 0.9×	253	4.3k
Takeshi Ueda Japan	32	2.0k 0.5×	207 0.2×	1.8k 1.4×	899 0.7×	1.2k 1.2×	156	4.2k
Kyoichi Kaira Japan	47	3.4k 0.9×	983 0.8×	3.3k 2.6×	1.5k 1.2×	4.3k 4.2×	425	9.1k
Jeri Kim United States	29	1.5k 0.4×	579 0.4×	1.3k 1.0×	581 0.5×	1.2k 1.2×	101	3.3k

Countries citing papers authored by Lynn Seely

Since Specialization

Citations

This map shows the geographic impact of Lynn Seely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynn Seely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynn Seely more than expected).

Fields of papers citing papers by Lynn Seely

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynn Seely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynn Seely. The network helps show where Lynn Seely may publish in the future.

Co-authorship network of co-authors of Lynn Seely

This figure shows the co-authorship network connecting the top 25 collaborators of Lynn Seely. A scholar is included among the top collaborators of Lynn Seely based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynn Seely. Lynn Seely is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Scher, Howard I., Karim Fizazi, Fred Saad, et al.. (2012). Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine. 367(13). 1187–1197. 3326 indexed citations breakdown →

Doody, Rachelle S., Bengt Winblad, Jeffrey L. Cummings, et al.. (2012). O3‐13‐06: Dimebon in Alzheimer's disease: Summary and contrast of three efficacy trials. Alzheimer s & Dementia. 8(4S_Part_12). 1 indexed citations

Scher, Howard I., Tomasz M. Beer, Celestia S. Higano, et al.. (2010). Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. The Lancet. 375(9724). 1437–1446. 809 indexed citations breakdown →

Doody, Rachelle S., Pierre N. Tariot, Jeff Cummings, et al.. (2010). S4‐01‐02: Results from CONNECTION: A global, Phase 3 double‐blind, placebo‐controlled confirmatory trial of dimebon (latrepirdine) in patients with mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia. 6(4S_Part_5).

Tariot, Pierre N., et al.. (2009). P1‐254: A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer's disease already receiving donepezil. Alzheimer s & Dementia. 5(4S_Part_8). 6 indexed citations

Doody, Rachelle S., Gavrilova Si, Mary Sano, et al.. (2008). Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. The Lancet. 372(9634). 207–215. 341 indexed citations

Cummings, Jeffrey L., Rachelle S. Doody, Gavrilova Si, et al.. (2008). P4‐334: Eighteen‐month data from an open‐label extension of a one‐year controlled trial of dimebon in patients with mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia. 4(4S_Part_24). 2 indexed citations

Doody, Rachelle S., Lynn Seely, Ronald G. Thomas, Mary Sano, & Paul Aisen. (2008). Statistical treatment of withdrawal in trials of anti-dementia drugs – Authors' reply. The Lancet. 372(9647). 1383–1383. 5 indexed citations

Doody, Rachelle S., Gavrilova Si, Ronald G. Thomas, et al.. (2008). P4‐337: Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one‐year, double‐blind, placebo‐controlled study. Alzheimer s & Dementia. 4(4S_Part_24). 1 indexed citations

10.

Doody, Rachelle S., Gavrilova Si, Mary Sano, et al.. (2007). S3–02–03: Results of a one‐year randomized, placebo‐controlled trial of dimebon for the treatment of mild to moderate Alzheimer's disease. Alzheimer s & Dementia. 3(3S_Part_3). 2 indexed citations

11.

Conte, Michael S., Dennis F. Bandyk, Alexander W. Clowes, et al.. (2006). Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. Journal of Vascular Surgery. 43(4). 742–751.e1. 479 indexed citations breakdown →

12.

Conte, Michael S., Dennis F. Bandyk, Alexander W. Clowes, et al.. (2005). Risk factors, medical therapies and perioperative events in limb salvage surgery: Observations from the PREVENT III multicenter trial. Journal of Vascular Surgery. 42(3). 456–464. 114 indexed citations

13.

Yip, Cecil C., et al.. (1993). Preparation of insulin-like growth factor I and photoaffinity labeling of insulin-like growth factor I receptor. Peptides. 14(2). 325–330. 2 indexed citations

14.

Bonadonna, Riccardo C., Maria Pia Saccomani, Lynn Seely, et al.. (1993). Glucose Transport in Human Skeletal Muscle: The In Vivo Response to Insulin. Diabetes. 42(1). 191–198. 81 indexed citations

15.

Bonadonna, Riccardo C., et al.. (1993). Glucose transport in human skeletal muscle. The in vivo response to insulin. Diabetes. 42(1). 191–198. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact